explore -WSS

explore

author：comprehensive 2025-09-30 16:26:40 - browse：8451

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Heart disease in astronauts blamed on cosmic radiation

focus

WSS

Eye stem cell transplant could help restore vision in injured people

Baltimore teen accused of firing into crowd during block party mass shooting

Patient advocates sound warning on FDA proposal on salt intake

Listen: Racing for gene therapy & a pioneering approval

CDC recommends RSV monoclonal antibody for infants

Biotech startup Celsius cuts 75% of staff ahead of first trial start

focus

explore

Bluebird and the case for gene therapy profits

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

'Null' research findings aren't empty of meaning. Let's publish them

As demand for Covid shots wanes, Moderna seeks its next success

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Wildfire smoke exposes gaps in outdoor worker protections

How to ethically and practically extend health care to all

As demand for Covid shots wanes, Moderna seeks its next success

Lung cancer is America's deadliest cancer. Yet so few get screened

Sports medicine is finally prioritizing gender equality

Alnylam reports growth in sales of rare disease treatments

hotspot

Eye stem cell transplant could help restore vision in injured people

Hilary expected to bring catastrophic, life

Late stage cancers on the rise after pandemic delayed screenings

ActiGraph execs on goal of drug approvals with digital endpoints

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Liz Cheney makes 1st public comment since Trump's election interference indictments

entertainment

hotspot

focus

focus